CURE Pharmaceutical Shakes Up Its Board
CURE Pharmaceutical Holdings (OTCQB: CURR) chairman William Yuan is transitioning to Chairman Emeritus and will remain in the company as a key advisor.
Rubén José King-Shaw Jr, who serves on the company’s board, opted to replace Yuan.
King-Shaw brings over thirty years of experience in healthcare technology and also private equity sectors.
Currently, he serves as CSO of Steward Health Care Systems, LLC.
In addition, the company appointed Dov Szapiro to its board. He serves as co-founder, managing partner and principal of Entourage Effect Capital.
“We thank Mr. Yuan for his dedicated leadership of CURE’s Board of Directors, and we are honored to have him stay with us as Chairman Emeritus and Key Advisor to the Board and executive team, as he leads the Company in its continued progress for dynamic international expansion and global revenue traction,” CURE chief executive Rob Davidson noted.